Disease or Syndrome
RFK Jr. Fires Top HHS Leadership in Major Department Shakeup
RFK Jr.; HHS; leadership shakeup; chief of staff replaced; Heather Flick Melanson; Hannah Anderson; Matt Buckham; health policy; White House liaison
RFK Jr. Reshuffles Top HHS Leadership, Replacing Chief of Staff and Deputy Chief
RFK Jr.; HHS; leadership shakeup; chief of staff; Heather Flick Melanson; Hannah Anderson; Matt Buckham; staff changes; federal health policy
RFK Jr. Reshuffles Top HHS Leadership, Names New Acting Chief of Staff
RFK Jr.; HHS; leadership shakeup; chief of staff; personnel changes; Matt Buckham; Heather Flick Melanson; Hannah Anderson; health policy; Department of Health and Human Services
RFK Jr. Fires Two Top Aides in Major HHS Leadership Reshuffle
Robert F. Kennedy Jr.; HHS; chief of staff; leadership shakeup; personnel change; Make America Healthy Again
RFK Jr. Reshuffles Top Leadership at HHS, Replaces Chief of Staff and Deputy Policy Chief
RFK Jr.; HHS leadership shakeup; chief of staff replaced; Heather Flick Melanson; Hannah Anderson; Matt Buckham; personnel changes; Make America Healthy Again
Otsuka Inks $613M Deal for Cantargia’s Autoimmune Antibodies
Otsuka Pharmaceutical; Cantargia; autoimmune diseases; IL1RAP antibodies; CAN10; biotech deal; hidradenitis suppurativa; systemic sclerosis; milestone payments; global commercialization
Outsmarting Data Bottlenecks in Pharma: The Clinical Terminology Advantage
data bottlenecks; clinical terminology; pharmaceutical industry; data integration; interoperability; regulatory compliance; AI in pharma; patient outcomes
Vertex, NHS England Finalize Reimbursement Deal for CF Drug Alyftrek
Vertex; NHS England; Alyftrek; cystic fibrosis; reimbursement agreement; triple therapy; CFTR gene mutation; NICE; UK healthcare
Veru Survey Highlights Muscle Loss Concerns Among GLP-1 Users as Lean Mass-Preserving Drug Advances
Veru; GLP-1 receptor agonists; muscle loss; enobosarm; lean mass; obesity; survey; older adults; high-protein diet
LEO Pharma Acquires Exclusive Global Rights for Boehringer Ingelheim’s Psoriasis Drug Spevigo in €90 Million Deal
LEO Pharma; Boehringer Ingelheim; Spevigo; spesolimab; psoriasis; GPP; drug licensing; immunology; IL-36 receptor; partnership; biotech news